Introduction

The European Union’s medical device regulations have undergone significant transformation with the shift from the Medical Device Directive (MDD) to the Medical Device Regulation (MDR) and from the In Vitro Diagnostic Directive (IVDD) to the In Vitro Diagnostic Regulation (IVDR). These changes aim to enhance patient safety, improve market oversight, and standardize compliance requirements across the EU.

For manufacturers, these regulatory shifts introduce stricter requirements for classification, clinical evaluation, post-market surveillance, and Notified Body involvement. This blog provides an in-depth look at what’s changing and how companies can prepare for MDR and IVDR compliance.

Understanding the Transition from MDD to MDR – New Classification Rules

Why the Shift from MDD to MDR?

The Medical Device Regulation (MDR 2017/745) replaces the MDD (93/42/EEC) and AIMDD (Active Implantable Medical Devices Directive 90/385/EEC). The key reasons for this transition include:

• Stronger clinical evidence requirements to ensure safety and effectiveness.
• Tighter post-market surveillance (PMS) & vigilance reporting.
• Expanded device classification system with stricter oversight of high-risk devices.

New MDR Classification Rules & Impact

Under the MDR, many devices have been reclassified into higher risk categories, leading to stricter requirements for clinical data and Notified Body assessment.

Device Type	Old Classification (MDD)	New Classification (MDR)
Standalone Software	Class I	Class IIa, IIb, or III (based on function)
Reusable Surgical Instruments	Class I	Class IIa
Spinal Implants	Class IIb	Class III
Nanotechnology-Based Devices	Not Clearly Defined	Class III

 Key Takeaway: Manufacturers must review their device classification under MDR and prepare additional clinical and technical documentation if their device has moved to a higher-risk category.

Key Changes in IVDR & Impact on IVD Manufacturers

Why the Shift from IVDD to IVDR?

The IVDR 2017/746 replaces the IVDD (98/79/EC) and significantly increases regulatory scrutiny for In Vitro Diagnostic (IVD) devices, such as laboratory tests, genetic screening kits, and blood glucose monitors.

New IVDR Classification System

Under IVDD, only 20% of IVDs required Notified Body certification, but under IVDR, this has increased to nearly 80%.

Device Type	Old Classification (IVDD)	New Classification (IVDR)
General Laboratory Reagents	Not Classified	Class A (Self-Certification)
Pregnancy Tests, Cholesterol Meters	Self-Certified	Class B (Notified Body Required)
Blood Glucose Meters, Genetic Tests	Self-Certified	Class C (Notified Body Required)
HIV, Hepatitis Tests	Self-Certified	Class D (Highest Risk)

Key Takeaway: Most IVD manufacturers must now work with a Notified Body to obtain IVDR certification, leading to longer approval timelines.

Notified Body Involvement: What to Expect?

Why Notified Bodies Play a Critical Role

Under MDR and IVDR, Notified Bodies (NBs) must now assess a greater number of devices, increasing their workload and leading to approval delays.

Key Challenges with Notified Bodies

• Limited Availability – Fewer Notified Bodies are designated under MDR/IVDR compared to MDD/IVDD.
• Longer Review Times – NBs require more clinical and technical documentation than before.
• Higher Costs – MDR and IVDR submissions involve higher fees and re-certification expenses.

Key Takeaway: Manufacturers should engage early with Notified Bodies and prepare comprehensive technical documentation to avoid certification delays.

Clinical Evaluation & Post-Market Surveillance (PMS) Updates

Clinical Evidence Requirements Under MDR

• Stronger Clinical Data Expectations – MDR requires more robust clinical evaluation reports (CERs), especially for Class III devices.
• Post-Market Clinical Follow-up (PMCF) – Companies must conduct ongoing clinical studies to monitor device performance.

PMS & Vigilance Reporting Under MDR & IVDR

• Manufacturers must implement a structured Post-Market Surveillance (PMS) plan to track device safety.
• Serious Incidents must be reported within 15 days to regulators.
• Periodic Safety Update Reports (PSUR) required for higher-risk devices.

Key Takeaway: Companies must invest in continuous monitoring, clinical evaluations, and proactive risk management to stay compliant.

Strategies for Ensuring EU MDR/IVDR Readiness

With increased scrutiny, stricter clinical evidence requirements, and limited Notified Body availability, manufacturers must take proactive steps to ensure MDR/IVDR compliance.

Key Steps to Ensure Compliance

Review Product Portfolio & Classifications

• Identify devices impacted by classification changes and determine new regulatory requirements.
• For IVDR, ensure all self-certified devices comply with new Notified Body rules.

Engage with a Notified Body Early

• Notified Bodies have long lead times—start discussions at least 12-18 months in advance.
• Prepare gap assessments to align technical documentation with MDR/IVDR requirements.

Strengthen Clinical Evaluation & Risk Management

• Collect real-world evidence and post-market data to support CERs and PMCF requirements.
• Ensure ISO 14971-compliant risk management processes are in place.

Implement Robust Post-Market Surveillance (PMS) Processes

• Establish clear tracking, complaint handling, and incident reporting systems.
• Maintain PSURs and continuously monitor device performance.

Stay Up-to-Date with Regulatory Changes

• Monitor EU Commission updates, MDCG guidance documents, and Notified Body announcements.
• Attend industry events, webinars, and regulatory training sessions.

Key Takeaway: Companies that start early, engage with Notified Bodies proactively, and invest in regulatory readiness will achieve MDR/IVDR compliance with fewer delays.

Conclusion

The transition from MDD to MDR and IVDD to IVDR represents one of the most significant regulatory shifts in the medical device industry. With stricter classification rules, expanded Notified Body oversight, and higher expectations for clinical evidence and post-market surveillance, manufacturers must take proactive steps to ensure compliance and maintain market access in the EU.